Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Baselga, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baselga, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 12:S49-S55, 2001
© 2001 European Society for Medical Oncology

Symposium Article

Phase I and II clinical trials of trastuzumab

J. Baselga

Medical Oncology Service, Hospital General Universilari Vall d'Hebron Barcelona, Spain

Correspondence to: J. Baselga, MD Medical Oncology Service Hospital General Universitari Vall d'Hebron Psg.Vall d'Hebron, 119–129 08035 Barcelona Spain E-mail: baselga{at}hg.vhebron.es

This report summarizes the efficacy of trastuzumab (Herceptin) based on its completed clinical trial program in patients with HER2-positive metastatic breast cancer for phase I and II studies which have been completed to date and were integral in the submission that led to approval of trastuzumab for clinical use in the USA. There were three small-scale, phase I clinical trials conducted, which were primarily designed to determine the safety and pharmacokinetics of trastuzumab (10–500 mg) administered i.v. as single or weekly doses. This was followed by two phase II clinical trials of fixed-dose trastuzumab either as a single-agent or in combination with cisplatin in 46 and 39 patients, which produced overall response rates of 11.6% and 24.3%, respectively. In a pivotal phase II clinical trial, trastuzumab was administered on a bodyweight-adjusted basis as a single agent to 222 patients with HER2-positive metastatic breast cancer who had relapsed after one or two prior chemotherapy regimens. The overall response rate was 21% when assessed in evaluable patients by the investigators and 15% when analyzed on an intent-to-treat basis by an independent Response Evaluation Committee. The pharmacokinetics of trastuzumab were evaluated in these studies and the results are summarized.

cisplatin, clinical trial, Herceptin, metastatic breast cancer, pharmacokinetics, trastuzumab


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
D. E. Milenic, K. Garmestani, E. D. Brady, P. S. Albert, D. Ma, A. Abdulla, and M. W. Brechbiel
Targeting of HER2 Antigen for the Treatment of Disseminated Peritoneal Disease
Clin. Cancer Res., December 1, 2004; 10(23): 7834 - 7841.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Thurm, S. Ebel, C. Kentenich, A. Hemsen, S. Riethdorf, C. Coith, D. Wallwiener, S. Braun, C. Oberhoff, F. Janicke, et al.
Rare Expression of Epithelial Cell Adhesion Molecule on Residual Micrometastatic Breast Cancer Cells after Adjuvant Chemotherapy
Clin. Cancer Res., July 1, 2003; 9(7): 2598 - 2604.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. Hayakawa, C. Depatie, M. Ohmichi, and D. Mercola
The Activation of c-Jun NH2-terminal Kinase (JNK) by DNA-damaging Agents Serves to Promote Drug Resistance via Activating Transcription Factor 2 (ATF2)-dependent Enhanced DNA Repair
J. Biol. Chem., May 30, 2003; 278(23): 20582 - 20592.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. M. R. Gilmour, K. G. Macleod, A. McCaig, J. M. Sewell, W. J. Gullick, J. F. Smyth, and S. P. Langdon
Neuregulin Expression, Function, and Signaling in Human Ovarian Cancer Cells
Clin. Cancer Res., December 1, 2002; 8(12): 3933 - 3942.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.